TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05726695

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart ultrasound examination
Description: Heart ultrasound examination will be performed as a standard cardiology examination.
Study: NCT01447771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision control preference scale
Description: At time 1, participants in the intervention group will be asked to complete the Decision Control Preference Scale.The range of decision control is measured by the Decision Control Preference (DCP) Scale. The scale is used to measure the preferred or actual role in decision making using five response statements: two represent an active or patient-controlled role, one a shared or collaborative role, and two represent a passive or provider-controlled role. The preferred level of decision making control will be known by the participant in the intervention group and the information given to the oncologist prior to the consultation regarding adjuvant therapy
Study: NCT01773824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Antibiotic prescription feedback
Description: Monthly postal and electronic feedback on antibiotic prescription rates

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Feedback
Description: Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial)
Study: NCT00702624

Intervention type: DRUG
Intervention: Corifollitropin alfa
Description: Single injection of 100 μg corifollitropin alfa administered under protocol P05690

Intervention type: BIOLOGICAL
Intervention: recFSH (follitropin beta)
Description: Daily recFSH administered under protocol P05690

Intervention type: DRUG
Intervention: gonadatropin releasing hormone (GnRH) antagonist ganirelix
Description: GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690

Intervention type: DRUG
Intervention: gonadatropin releasing hormone (GnRH) antagonist ganirelix
Description: GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690

Intervention type: BIOLOGICAL
Intervention: human chorion gonadotropin (hCG)
Description: hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690

Intervention type: BIOLOGICAL
Intervention: human chorion gonadotropin (hCG)
Description: hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690

Intervention type: BIOLOGICAL
Intervention: progesterone
Description: Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.

Intervention type: BIOLOGICAL
Intervention: progesterone
Description: Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.

Intervention type: DRUG
Intervention: placebo-recFSH (follitropin beta)
Description: Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690

Intervention type: DRUG
Intervention: placebo-corifollitropin alfa
Description: Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690

Intervention type: BIOLOGICAL
Intervention: open-label recFSH (follitropin beta)
Description: Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690

Intervention type: BIOLOGICAL
Intervention: open-label recFSH (follitropin beta)
Description: Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690
Study: NCT04008212

Intervention type: OTHER
Intervention: Fusion imaging
Description: Fusion imaging during aortic endovascular procedures with a mobile C-arm through the use of the EndoNaut® angio-navigation station

Intervention type: OTHER
Intervention: Fusion imaging
Description: Fusion imaging during aortic endovascular procedures with a mobile C-arm through the use of the EndoNaut® angio-navigation station
Study: NCT02988648

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radioiodide (131I-)
Description: The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
Study: NCT03037216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: 10 Week aerobic exercise training
Study: NCT03139370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KITE-718
Description: A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGE - A3/A6 Screening Test
Description: A screening test for MAGE-A3/A6+ tumors
Study: NCT03154138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The prismatic adaptation (PA)
Description: Prismatic adaptation (PA) is based on the wearing of a pair of glasses producing a visual field deviation of 10° to rightward. While wearing theses glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements with a shift toward the right side (initial errors consecutive to the prism deviation). Taking into account theses errors, the patient then compensates the optical deviation. After removing the prismatic glasses, the asked pointing movement to the targets is once again shifted but to the left side this time (after-effects attesting the prismatic adaptation)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The sham prismatic adaptation (S-PA)
Description: The sham prismatic adaptation (S-PA) is based on the wearing of a pair of glasses producing no visual field deviation. Theses sham glasses is identical with theses used in PA group without the optical deviation. The conditions are similar with theses in the PA group.~The procedure with the sham glasses are similar with these one used in the PA group: While wearing the sham glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The support with targets are the same as these one used in the PA group. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements without shift. No compensation of movement is observed. After removing the prismatic glasses, the asked pointing movement to the targets is not shifted (No after-effects observed)
Study: NCT02362607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Diabetes Management Protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Management Protocol
Study: NCT02298244

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV isolation + GP Ablation
Description: In real time builds the 3D card LA using nonfluoroscopic navigation system.Left and right PVs encircle in 1 lesion line by circumferential PV isolation.Radiofrequency energy delivered at 43◦C,35 W,0.5 cm away from the PV ostia at the anterior wall,and reduced to 43◦C,30 W,1 cm away from the PV ostia at the posterior wall,with a saline irrigation speed of 17 ml/min.Each lesion of ablation continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 seconds.The endpoint of circumferential PV isolation is PV isolation;this confirm when Lasso mapping show the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.To accomplish ganglionated plexi ablation,LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter HFS.Rectangular electrical stimuli were delivered at a frequency of 50 Hz,output amplitude 15V and pulse duration of 10 ms,for 5 sec
Study: NCT02465060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Optional correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib Mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Given PO
Study: NCT01172301

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential amino acid intake + Leucine vs total AA supplement
Description: 7 g as bolus
Study: NCT03729596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Anti-B7H3 antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Anti-B7H3 antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Anti-B7H3 antibody drug conjugate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: Anti-B7H3 antibody drug conjugate
Study: NCT02465060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib Hydrochloride
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography (ECHO)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography (ECHO)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography (ECHO)
Study: NCT03249454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Description: During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Description: During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Description: During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS
Description: During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
Study: NCT02037867

Intervention type: DEVICE
Intervention: Fibrosis Biomarkers
Description: Liver disease stratification with liver stiffness scan (Transient Elastography) Analysis of diagnostic performance of serum fibrosis markers (as listed above) Whole blood samples obtained for DNA analysis
Study: NCT02298244

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV isolation + GP ablation + Pulmonary GP ablation
Description: The procedure of AF ablation is the same like in the circumferential PV isolation + GP Ablation.~8-Fr sheath is carried through the right heart into the pulmonary artery trunk. Using ablation electrode constructed 3D map of the pulmonary artery trunk and the right and left main branches. Further HFS performed with the tip ablation electrode at the bifurcation of the pulmonary artery and in the ostium of the left and right pulmonary arteries (less than 2 mm distal to the bifurcation) 20 Hz, duration of each stimulus 10 ms. A positive response would be considered an increase in the RR interval of more than 50% of baseline within 10 seconds. In areas with a positive response to HFS, will be performed RFA Efficiency criterion: no previously described responses to HFS in the ablation area. Parameters RFA: 8-10 watts for 60 seconds duration at one point, the irrigation speed of 5 ml / min.
Study: NCT02914626

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravitreal ranibizumab
Description: Intravitreal ranibizumab injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab
Description: Intravitreal ranibizumab injection
Study: NCT00601718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study: NCT02968030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strength
Description: Strength training The strength training for lower limbs muscles occurred twice a week, 40 minutes per session for eight consecutive weeks.~n the first two weeks of training, each elderly performed the exercises with 50% of its load defined in 8RM test, increasing to 60 and 70% of the load in the third and fourth subsequent weeks, respectively. After this period, a new evaluation by 8RM strength test was conducted, adopting the fifth and sixth weeks of training 50% of value of the new load defined in 8RM test and to finalize the program in seventh and eighth weeks applied, respectively, 60% and 70% of the new charge. The exercises were performed for the quadriceps, hamstrings, muscles adductor and abductor hip.
Study: NCT02669563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]4F-MHPG
Description: IV injection of \[18F\]4F-MHPG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]4F-MHPG
Description: IV injection of \[18F\]4F-MHPG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]3F-PHPG
Description: IV injection of \[18F\]3F-PHPG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]3F-PHPG
Description: IV injection of \[18F\]3F-PHPG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13N]ammonia
Description: IV injection of \[13N\]ammonia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13N]ammonia
Description: IV injection of \[13N\]ammonia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]HED
Description: IV injection of \[11C\]HED
Study: NCT02985346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis
Study: NCT00841724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine, Busulfan, Thymoglobuline
Study: NCT02506777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoruracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoruracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoruracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Study: NCT01576081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPHAISTOS
Description: HEPHAISTOS unloading orthotic
Study: NCT00476086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT02465060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography (ECHO)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography (ECHO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO
Study: NCT03249454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS
Description: During Cathodal tsDCS intervention the negative end of the battery will be connected to the electrode on participant's back and positive end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS
Description: During Cathodal tsDCS intervention the negative end of the battery will be connected to the electrode on participant's back and positive end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tsDCS
Description: During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tsDCS
Description: During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tsDCS
Description: During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tsDCS
Description: During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tsDCS
Description: During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tsDCS
Description: During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tsDCS
Description: During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tsDCS
Description: During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tsDCS
Description: During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tsDCS
Description: During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tsDCS
Description: During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.
Study: NCT02220335

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary arterial denervation
Description: Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
Study: NCT04131868

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Typical sleep opportunity
Description: Typical sleep opportunity with consistent sleep timing for 1 week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended sleep opportunity
Description: Extended sleep opportunity by 90 min per night with consistent sleep timing for 1 week